

**An Important Message from
The Texas Health and Human Services Commission
(HHSC)**

**Change in Preferred Drug List Status for Lincosamides/
Oxazolidinones/ Streptogramins Drug Class Effective May 6, 2024**

Key Details:

The manufacturer of brand name Zyvox suspension, Pfizer, confirmed these products are on long term backorder. In response, the HHSC removed the non-preferred status from generic linezolid suspension products on the preferred drug list (PDL). The preferred status of brand name Zyvox suspension products will not change. This will allow the current stock of these medications to be used.

HHSC removed the non-preferred status for the following drugs, effective May 7, 2024.

NDC	Label Name
00054031950	LINEZOLID 100 MG/5 ML SUSP
31722086525	LINEZOLID 100 MG/5 ML SUSP

These changes will allow providers to prescribe the generic linezolid suspension products without requiring a PDL prior authorization and continue accessing necessary medication for clients. MCOs may reference the PDL formulary file delivered on March 29, 2024, and must make this change by May 13, 2024.

Questions?

Please contact your physician advocate or call UnitedHealthcare Provider Services, toll-free, at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.